Breast Cancer

From a Small Town in the Rust Belt, Dennis J. Slamon, MD, PhD, Plays a Big Role in Changing the Face of Breast Cancer Treatment

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Dennis J. Slamon, MD, PhD, one of the principals in...

Breast Cancer

Lobular vs Ductal Breast Cancer: Distinctions in Management

As a relatively rare subtype, lobular breast cancer is not well understood by many oncologists. At the 2023 Miami Breast Cancer Conference, Tari A. King, MD, FASCO, described...

Breast Cancer

Younger Postmenopausal Patients With Early-Stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy

Almost all postmenopausal patients aged 50 to 69 years with stage I hormone receptor–positive breast cancer and low scores on a common genetic test...

Breast Cancer

Incidence of Breast Cancer After False-Positive Mammography

In a Swedish study reported in JAMA Oncology, Mao et al found that women with a false-positive mammography result were more likely to be subsequently...

Breast Cancer
Supportive Care

Novel Selective Biomarker Tool May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer

A novel selective biomarker tool (Troplex) may help select which antibody-drug conjugate therapy could be most effective in patients with metastatic breast cancer...


Breast Cancer

Dennis J. Slamon, MD, PhD, on Exploiting Cancer Biology in Developing New Treatment Paradigms

Issues in Oncology

Predictors of Emergency Department Visits After a New Diagnosis of Cancer

In a retrospective cohort study reported in JCO Oncology Practice, Hong et al found that prior frequent emergency department use was the strongest predictor of postdiagnosis emergency department visits among patients with a new diagnosis of cancer. Study Details The study involved data from...


Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Lung Cancer

Pasi A. Janne, MD, PhD, on NSCLC: Patritumab Deruxtecan to Target HER3

Gynecologic Cancers

HIPEC With Carboplatin for Platinum-Sensitive Recurrent Ovarian Cancer: Safety and Outcomes

In an MSK Team Ovary–led phase II trial reported in the Journal of Clinical Oncology, Zivanovic et al found that use of hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin during secondary cytoreduction followed by chemotherapy did not improve 24-month progression-free survival in...


Remote Monitoring Program Reduced Hospitalization Among Patients With Cancer Infected With COVID-19

A study by researchers at Mayo Clinic Cancer Center found that patients with cancer diagnosed with COVID-19 who received care at home via remote patient monitoring were significantly less likely to require hospitalization for their illness, compared to patients with cancer infected with the virus...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...


Ann S. LaCasce, MD, on Hodgkin Lymphoma: PET-Adapted Therapy for Bulky Disease

Breast Cancer

Study Examines Relationship Between Risk of COVID-19 Infection and Breast Cancer Treatment

In a study led by researchers at NYU Langone Health and its Perlmutter Cancer Center involving more than 3,000 women treated for breast cancer at the height of the COVID-19 pandemic in New York City, only 64 patients, or 2% of the total study population, contracted the virus. Of this group, 10 died ...


Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...